2[3]Insogna K，Concato J，Henrich，et al.Boning upon estrogen:new options，new concepts[J].JAMA，1996，276（17）:1430.
3Insongna K,Concato J,Henrich,et al .Boning upon estrogen :new options ,new concepts [J].JAMA,1996,276(17):1430－ 1432
4Consensus development conference,diagnosis,prophylaxis and treatment of osteoporosis[J].Am J Med,1993,94:646-650.
5Black DM,Reid IR,Boonen S,et al.The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis:A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)[J].J Bone Miner Res,2012,27(2):243-254.
6Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathyroid hormone(1 -34) on fracture and bone mineral density in postmenopausal women with osteoporosis[J].N Engl J Med,2001,344:1434-1441.
7Han SL,Wan SL.Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis:meta-analysis of randomized controlled trials[J].Int J Clin Pract,2012,66(2):199-209.
8Bekker PJ,Holloway D,Nakanishi A,et al.The effect of a single dose of osteoprotegerin in postmenopausal women[J].J Bone Miner Res,2001,16(2):348-360.
9Bone HG,Bolognese MA,Yuen CK,et al.Effects of denosumab on bone mineral density and bone turnover in postmenopausal women[J].J Clin Endocrinol Metab,2008,93:2149-2157.
10Cummings SR,Martin JS,McClung MR,et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J].N Engl J Med,2009,361:756-765.
